GALT

Galectin Therapeutics Inc.

2.81

USD

GALT Earnings Reports

Positive Surprise Ratio

GALT beat 29 of 40 last estimates.

73%

Next Report

Today AMC

Date of Next Report

Mar 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.10

Implied change from Q-- -- (Revenue/ EPS)

Implied change from Q4 24 (Revenue/ EPS)

-47.37%

Galectin Therapeutics Inc. earnings per share and revenue

On --, GALT reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

electroCore, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.34

Surprise

+18.15%

FAQ

What were Galectin Therapeutics Inc.'s earnings and revenue for the latest quarter Q-- --?

For Q-- --, Galectin Therapeutics Inc. reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.

How did the market react to Galectin Therapeutics Inc.'s Q-- -- earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Galectin Therapeutics Inc. expected to report next?

The next earning report is scheduled for Mar 26, 2026.

What are the forecasts for Galectin Therapeutics Inc.'s next earnings report?

Based on 3 analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.10 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.